相关实验视频

Updated: Jul 24, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

弥合差距:在渐进性多焦点白内障中免疫疗法:一个新的希望?

Tristan Born1, Paola Vassallo1, Dela Golshayan1

  • 1From the Neurology Service (T.B., P.V., G.D.L., R.A.D.P., R.B.-V.), Department of Clinical Neurosciences, Transplantation Center (D.G.), Department of Medicine, and Pathology Department (J.-P.B.), Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and the University of Lausanne; and Service of Clinical Pathology (K.E., D.M.), Department of Pathology and Immunology and Diagnostic Department, University Hospitals of Geneva, Switzerland.

Neurology
|July 5, 2023
PubMed

Insights

渐进性多焦点白内障 (PML) 是一种严重的中枢神经系统感染. 复合人间白蛋白7用于提高PML脏移植患者的抗JCV免疫力,显示出免疫恢复策略的前景.

科学领域:

  • 神经免疫学 神经免疫学
  • 病毒学 病毒学
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 渐进性多焦点白内障 (PML) 是一种严重的中枢神经系统脱髓性疾病,由免疫功能低下个体的JC病毒 (JCV) 引起.
  • 缺乏有效的PML抗病毒治疗方法,需要采取恢复抗JCV免疫力的策略.
  • 恢复免疫反应对于管理PML至关重要,特别是在长期免疫抑制的患者中,如器官移植接受者.
抽象的

No abstract available in PubMed .

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573